With box warnings

Without box warnings

Branded

Generic

3 results

balversa
(Erdafitinib)
Janssen Products LP
Usage: BALVERSA is indicated for treating adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with FGFR3 genetic alterations, following progression on at least one prior systemic therapy. Selection of patients must utilize an FDA-approved companion diagnostic. It is not recommended for those eligible for PD-1 or PD-L1 inhibitors.
opdivo
(nivolumab)
E.R. Squibb & Sons, L.L.C.
Usage: OPDIVO is indicated for the treatment of various cancers, including unresectable/metastatic melanoma, neoadjuvant and adjuvant non-small cell lung cancer, metastatic non-small cell lung cancer, malignant pleural mesothelioma, advanced renal cell carcinoma, classical Hodgkin lymphoma, and others. It is used in different combinations and settings based on the cancer type.
trodelvy
(SACITUZUMAB GOVITECAN)
Gilead Sciences
Usage: TRODELVY is indicated for treating adults with unresectable locally advanced or metastatic triple-negative breast cancer and certain hormone receptor-positive breast cancers after multiple systemic therapies. It also treats locally advanced or metastatic urothelial cancer in patients previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors.

Medications for Urothelial Carcinoma

balversa